AAO Digital GUIDELINES Apps (free trial)

Age-Related Macular Degeneration

AAO GUIDELINES App brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/557417

Contents of this Issue

Navigation

Page 7 of 15

6 Management Î Patients who are currently smoking should be advised to stop. (I++, G, S) Î Treatment with antioxidants and minerals as described previously in the original Age-Related Eye Disease Study (AREDS) and AREDS2 trials is recommended for patients who have progressed to intermediate or advanced age-related macular degeneration (AMD) in at least one eye. (I++, G, S) Î Patients with a high risk AMD phenotype are at increased risk of progression to advanced AMD and should be educated about methods of detecting new symptoms of choroidal neovascularization (CNV) including self-monitoring. (III, G, S) Î Patients with a high risk AMD phenotype should be educated about the need for promptly reporting new symptoms to an ophthalmologist who can confirm if the new symptoms are from CNV and who can begin any necessary treatment. (III, G, S) Î Electronic monitoring devices are now available to aid in the detection of neovascularization at an early stage. (I+, G, D) Î A history and examination are the recommended elements of the follow-up visits. (III, G, S) Î The follow-up history should take into account symptoms, including decreased vision and metamorphopsia. (II-, G, S) Î The follow-up history should take into account changes in medications and nutritional supplements. (III, G, S) Î The follow-up history should take into account changes in medical and ocular history. (II+, G, S) Î The follow-up history should take into account changes in social history (smoking). (III, G, S) Î The examination on the follow-up visit should include visual acuity. (III, G, S) Î The examination on the follow-up visit should include stereoscopic biomicroscopic examination of the fundus. (III, G, S) Î Patients who have been treated with aflibercept, bevacizumab, ranibizumab, or pegaptanib sodium injection; verteporfin photodynamic therapy (PDT); or thermal laser photocoagulation surgery should be examined at regular intervals by means of biomicroscopy of the fundus. (III, G, S) Î Optical coherence tomography (OCT), fluorescein angiography, and fundus photography may be helpful to detect signs of active exudation or disease progression and should be used when clinically indicated. (III, In, D)

Articles in this issue

Archives of this issue

view archives of AAO Digital GUIDELINES Apps (free trial) - Age-Related Macular Degeneration